WO2011123820A2 - Novel rhodamine dyes and conjugates - Google Patents

Abstract

The present invention relates generally to novel rhodamine dyes which upon conjugation with another molecule form single isomeric conjugation products. These novel rhodamine dyes contain only one single functional group on the rhodomine molecule for conjugation so that their conjugation products are single isomeric conjugation products.

Description

NOVEL RHOD AMINE DYES AND CONJUGATES

DESCRIPTION CROSS-REFERENCE TO RELATED APPLICATION

[0001] The present application claims the benefit of U.S. Provisional Patent Application No. 61/320,571 filed April 2, 2010, the contents of which are incorporated herein by reference.

FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

[0002] None.

FIELD OF THE INVENTION

[0003] The present invention relates generally to novel rhodamine dyes which upon conjugation with another molecule to form single isomeric conjugation products.

BACKGROUND OF THE INVENTION

[0004] Rhodamine dyes fluoresce and have been used extensively in research, both as free dye and as conjugates to larger molecules, e.g. proteins and antibodies (Lee S, McAuliffe DJ, Kodama T, Doukas AG, In vivo transdermal delivery using a shock tube, Shock Waves (2000) 10:307-307; Janson LW, Ragsdale K, Luby-Phelps K, Mechanism and size cutoff for steric exclusion from actin-rich cytoplasmic domains., Biophys J (1996) 71: 1228-1234; Pu R, Robinson KR, Cytoplasmic calcium gradients and calmodulin in the early development of the fucoid alga Pelvetia compressa., J Cell Sci (1998) 111 ( Pt 21):3197-3207; Nishiya T, Kajita E, Horinouchi T, Nishimoto A, Miwa S, Distinct roles of TIR and non-TIR regions in the subcellular localization and signaling properties of MyD88, FEBS Lett (2007) 581 :3223- 3229; Tanner GA, Sandoval RM, Dunn KW, Two-photon in vivo microscopy of

sulfonefluorescein secretion in normal and cystic rat kidneys, Am J Physiol Renal Physiol (2004) 286:F152-F160).

[0005] Structurally, rhodamine is a family of related polycyclic flurone dyes with a xanthene core.

Xanthene

[0006] The general structure of rhodamine is as follows:

Rhodam ine

[0007] The amines of rhodamine can be primary amines, secondary amines or tertiary amines.

[0008] One of the commonly used fluorescent rhodamine dye is sulforhodamine 101 which contains a julolidine structure element:

Julolidine structure element [0009] Sulforhodamine 101 contains bi-functional sulfonyl groups as shown below:

Sulforhodamine 101 [0010] Sulfonylrhodamine 101 has been used in neurophysiological experiments which comprise calcium imaging methods as well as a counterstaining of astrocytes (Nimmerjahn, A., Kirchhoff, F., Kerr, J.N., Helmchen, F., Sulforhodamine 101 as a specific marker of astroglia in the neocortex in vivo, Nature Methods (2004) 1 : 31-7).

[0011] A sulfonyl chloride derivative of sulforhodamine 101 is sold by Sigma Aldrich, Inc. (St. Louis, MO) under the trademark Texas Red®. It is used for conjugation with a number of functional groups, especially with primary amines. Texas Red® fluoresces at about 615 nm with a peak absorption at 589 nm. Texas Red® is typically available as a mixture of two monosulfonyl chlorides with the S0₃ and S0₂C1 groups exchangeable as shown below:

[0012] Other rhodamine derivatives have also been disclosed, such as in PCT Int. Appl. (2009), WO 2009108905 A2 20090903; U.S. Pat. Appl. Publ. No. 2004054162 Al

20040318; U.S. Pat. No. 5728529; U.S. Pat. No. 5686261; PCT Int. Appl. (1997), WO 9700967 Al 19970109; U.K. Pat. Appl. (1995), GB 2283744 A 19950517; and by Kim etl al. (Kim, T. G.; Castro, J. C; Loudet, A.; Jiao, J. G.-S.; Hochstrasser, R. M.; Burgess, K.; Topp, M. R., Journal of Physical Chemistry A (2006), 110(1), 20-27). [0013] Although several publications show the possibility of using bi-functional rhodamine dyes for conjugation, e.g. by selective reaction of one of the sulfonyl chloride groups in Texas Red® (Titus JA, Haugland R, Sharrow SO, Segal DM, Texas Red, a hydrophilic, red-emitting fluorophore for use with fluorescein in dual parameter flow microfluorometric and fluorescence microscopic studies, J. Immunol. Methods (1982) 50 (2): 193-204), the possibility of dual reactivity gives difficulties in establishing a reliable process yielding a single isomer product only, which is shown in FIG. 1 in which a bi-functional rhodamine dye with two sulfonyl groups reacting with a primary amine to form two conjugation isomeric products. Two isomeric structures instead of only one in a process gives two major disadvantages: 1) the ratio of isomers changes from batch to batch with product impacting effects, and 2) the regulatory requirements (toxicity data, stability,

characterization, etc) will be doubled to cover two substances instead of one.

[0014] The present invention circumvents these difficulties by using novel mono- functional derivatives of rhodamine dye with only one single functional group on the rhodomine molecule for conjugation so that their conjugation products are single isomeric conjugation products.

[0015] These and other aspects and attributes of the present invention will be discussed with reference to the following drawings and accompanying specification.

BRIEF DESCRIPTION OF THE DRAWINGS

[0016] FIG. 1 shows the conjugation of a bi-functional rhodamine dye with a

macromolecule to form two isomeric conjugation products;

[0017] FIG. 2 shows the conjugation of a mono-functional rhodamine dye with a macromolecule to form only one single isomeric conjugation product;

[0018] FIG. 3 shows the formation of the novel rhodamine dye of the present invention from 8-hydroxyjulolidine (2 equivalents) and a substituted benzaldehyde (1 equivalent) wherein R_l5 R₂, R₃, R₄ and R₅ can be a H or any group;

[0019] FIG. 4 shows the general conjugation reaction under the Ugi reaction conditions between a rhodamine dye with a mono-functional group and a macromolecule; and

[0020] FIG. 5 is an example of conjugation with the Ugi reaction of a mono-functional 2- sulforhodamine (2-SHR) dye having a single functional primary amino group with carboxmethylated dextran to form a single isomeric conjugation product; [0021] FIG. 6 is a UV absorption spectrum of Compound 18 scanning from 200 nm to 800 nm at a scan speed of 400 nm/minute;

[0022] FIG. 7 is a fluorescence emission scan of Compound 18;

[0023] FIG. 8 is a fluorescence excitation scan of Compound 18;

[0024] FIG. 9 is a 3 -dimensional fluorescence scan of Compound 18 wherein EM is the emission wavelength and EX is the excitation wavelength;

[0025] FIG. 10 is a UV absorption spectrum of the conjugate of Example 26 scanning from 200 nm to 800 nm at a scan speed of 400 nm/minute;

[0026] FIG. 11 is a fluorescence emission scan of the conjugate of Example 26;

[0027] FIG. 12 is a fluorescence excitation scan of the conjugate of Example 26; and

[0028] FIG. 13 is a 3 -dimensional fluorescence scan of the conjugate of Example 26 wherein EM is the emission wavelength and EX is the excitation wavelength.

DETAILED DESCRIPTION OF THE INVENTION

[0029] While this invention is susceptible of embodiments in many different forms, there are specific embodiments which will be described herein in detail with the understanding that the present disclosure is to be considered as an exemplification of the principles of the invention and is not intended to limit the invention to the specific embodiments illustrated.

[0030] It will be understood that the chemical structures that are used to define compounds of the present invention are each representations of one of the possible resonance structures that each given structures can be represented by. Further, it will be understood that by definition, resonance structures are merely a graphical representation used by those of skill in the art to represent electron delocalization, and that the present disclosure are not limited in any way by showing one particular resonance structure for a given structure.

[0031] It will also be understood that the chemical structures that are used to define compounds of the present invention also include their structures in their respective salt forms.

[0032] The present invention relates generally to novel rhodamine dyes which upon conjugation with another molecule to form single isomeric conjugation products.

[0033] Although several publications show the possibility of using bi-functional rhodamine dyes for conjugation, e.g. by selective reaction of one of the sulfonyl chloride groups in Texas Red® (Titus JA, Haugland R, Sharrow SO, Segal DM, Texas Red, a hydrophilic, red-emitting fluorophore for use with fluorescein in dual parameter flow microfluorometric and fluorescence microscopic studies, J. Immunol. Methods (1982) 50 (2): 193-204), the possibility of dual reactivity gives difficulties in establishing a reliable process yielding a single isomer product only. As shown in FIG. 1, a bi- functional rhodamine dye with two sulfonyl groups reacts with a primary amine to form two conjugation isomeric products. Two isomeric structures instead of only one in a process gives two major disadvantages: 1) the ratio of isomers changes from batch to batch with product impacting effects, and 2) the regulatory requirements (toxicity data, stability, characterization, etc) will be doubled to cover two substances instead of one.

[0034] The present invention circumvents these difficulties by using novel mono- functional derivatives of rhodamine dye with only one single functional group on the rhodomine molecule for conjugation so that their conjugation products are single isomeric conjugation products as illustrated in FIG. 2. FIG. 2 illustrates an example of the present invention in which a rohodamine derivative with a single sulfonyl group reacts with a primary amine to form only a single isomeric conjugation product. What is meant by a "functional group" is that the group is suitable for conjugation. The functional group suitable for conjugation is reactive to another molecule, such as a macromolecule, to form a conjugate via a covalent bond. A rhodamine derivative containing only one "functional group" is known as mono-functionalized or a mono-functional derivative (such as the mono-sulfonyl rhodamine in FIG. 2) which differentiates from rohodamine derivatives containing more than one "functional groups" such as sulfonylrhodamine 101 or Texas Red® . Examples of functional groups suitable for conjugation include but are not limited to amines, isocyanates, isothiocyanates, thiols, carboxylic acids and the like. "Functionalized" herein means that the rhodamine derivative has been derivatised to contain a "functional group". An example is "amino-functionalized" meaning that the functional group contains the reactive amino group.

[0035] In an embodiment, the novel rhodamine dyes of the present invention have a general structure of:

wherein Rl, R2, R3, R4 and R5 can be a H or any group. However, among Rl, R2, R3, R4 and R5, only one of these groups can have a "functional group" so that the rhodamine dye has only one single "functional group" capable of conjugation with another molecule, such as a macromolecule, to form a single conjugation isomeric product. This general structure can be formed by reacting 8-hydroxyjulodine (2 equivalents) with a substituted benzaldehyde (1 equivalent) as shown in FIG. 3. The 8-hydroxyjulodine and the substituted benzaldehyde can be mixed with 60% aqueous sulfuric acid (11.1 mL/mmol benzaldehyde) and stirred at 150 °C for 24 h under air atmosphere. The reaction mixture can be added to ice (28 g/mmol benzaldehyde), after which 60% NaOH can be carefully added to pH6-7 to precipitate the crude product. The crude product can be extracted between dichloromethane (DCM) and water. The organic phase can be separated, and washed with brine. The organic solvent can be removed and the final product dried by evaporating with ethanol and toluene 5 times to give the crude product. Detailed methods for preparing specific examples of the rhodamine dyes of the present invention are described in Examples below.

[0036] Some examples of general structures of mono-functional rhodamine derivatives suitable to form single isomeric conjugation products are shown below with the general formula of 2-sulforhodamine:

or the general formula of 4-carboxrhodamine:

or the general formula of 4-arylrhodamine:

wherein for all the above 4 general formulas, Ar is an aryl group, and Rl and/or R2 form a spacer with a single functional group on either Rl or R2 suitable for conjugation with another molecule, wherein the spacer can be, but is not limited to, hydrogen, alkyl, aryl, amide, alkyl sulfonamide, alkyl ether, alkyl amide and the like, or a combination thereof. The alkyl groups mentioned above preferably have a carbon chain length of from 1 to 20. Rl and R2 can also be connected to form a cyclic structure, such as but not limited to the structures shown below:

or

[0037] Although the examples shown above show that the sulfo-group is in the 2 position, the carbox-group is in the 3 or 4 position and the aryl-group is in the 4 poisiton, it should be noted that these and other groups containing the "functional" group can be in the 2, 3 or 4 position. The examples below (Examples 4-24) illustrate the synthesis of some of the members belonging to the groups shown above. However, the synthesis of other related compounds with the sulfo-, carbox- , aryl- or any other group positioning at any desired position in the novel rhodamine dye of the present invention should be obvious to those skilled in the art with the illustrations from the Examples.

[0038] In a preferred embodiment, the novel rhodamine derivatives are in the form of a salt, such as but are not limited to trifluoroacetate, chloride, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzensulfonate and p-toluenesulfonate.. In a further preferred embodiment, the salt is trifluoroacetate or chloride. In yet another preferred embodiment, the salt is a pharmaceutically acceptable salt.

[0039] One of the applications for these novel mono-functional rhodamine derivatives is their ability to conjugate to another molecule, such as a macromolecule. The molecule, such as a macromolecule, when conjugated to the rhodamine dye can be easily detectable and/or quantifiable. Commonly used macromolecules herein include but are not limited to polymers, proteins (such as antibodies), dextrans, celluloses, carbohydrates, lipids, nucleic acids (such as DNA and RNA) and the like. Conjugation of rhodamme dyes with

macromolecules and their applications are well known to those skilled in the art, and has been described in details in the scientific literature, such as disclosed by Titus et al. (Titus JA, Haugland R, Sharrow SO, Segal DM, Texas Red, a hydrophilic, red-emitting fluorophore for use with fluorescein in dual parameter flow microfluorometric and fluorescence microscopic studies, J. Immunol. Methods 50 (1982) 2: 193-204) and by Haugland et al. in United States Patent No. 5,798,276. Conjugates of rhodamine with macromolecules such as antibodies are readily commercially available such as Human IgG antibody conjugated with rhodamine from Abeam (Cambridge, MA) and various proteins conjugated with rhodamine dyes from Sigma Aldrich (St. Louis, MO). Any synthetic methodology that creates a covalent bond between the functional group of the dye and the macromolecule can be used for conjugation. The general conjugation reaction between the rhodamine dye and a macromolecule under the Ugi reaction conditions is illustrated in FIG. 4, exemplified by the conjugation of the amino- functionalized sulfonamide dye (Compound 1 shown in Example 6) to carboxymethylated dextran with the Ugi reaction, as shown in FIG. 5.

[0040] To illustrate the invention, a number of structures suitable for conjugation have been synthesized (Compounds 1-19) which are shown in the Examples 6-24 below.

Experimental details of further examples of conjugations are shown with Examples 25-28 below, using dyes from the synthesized examples (Compound 18, Compound 3, Compound 15 and Compound 16) conjugating with carboxymethylated-dextran (CM-dextran).

[0041] While the present invention is described in connection with what is presently considered to be the most practical and preferred embodiments, it should be appreciated that the invention is not limited to the disclosed embodiments, and is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the claims. Modifications and variations in the present invention may be made without departing from the novel aspects of the invention as defined in the claims. The appended claims should be construed broadly and in a manner consistent with the spirit and the scope of the invention herein.

Examples

[0042] Solvents and reagents are used as received from Labscan (Gliwice, Poland) and Sigma Aldrich (St. Louis, MO), respectively. A Liquid Chromatography-Mass Spectroscopy (LCMS) system from Agilent Technologies (Santa Clara, CA) is used, which consists of a G1379B degasser, a G1312A binary pump, a G1329A autoinjector, a G1316A column oven, a G1365B UV-Vis detector (used to detect absorbance maxima) and a 6110 Quadrupole MS detector. High Performance Liquid Chromatography (HPLC) purities are measured with an ACE-C8 column (50 x 4.6 mm) held at 35° C and eluted with 10-97% acetonitrile in 0.1% trifluoral acetic acid (TFA) over a 3 minute gradient.

[0043] The compounds in the following Examples are named based on Marvin Sketch 5.2.6, using Preferred IUPAC naming settings for structure naming. However, other nomenclature systems can be employed to name these compounds. Example 1 : Preparation Intermediate 1

[0044] The following compound is repared:

Intermediate 1

[0045] A reaction mixture of 8-hydroxyjulolidine (1. lg, 5.8 mmol) and sodium 2- formylbenzene-1 -sulfonate (0.6 g, 2.9 mmol) in 60% aqueous H₂S0₄ (10 mL) is stirred at 150° C under an air atmosphere for 2 hours, after which time the starting materials have converted to the expecting product completely. pH of the reaction is adjusted to about 7 with aqueous 60% of NaOH, in which procedure the expecting product is precipitated. The precipitation is filtered and washed with toluene (3 X 50 mL) and dried under vacuum. The crude product is dissolved in warm ethanol (EtOH) and filtered. Insoluble solid is discarded, and the filtrate is evaporated in vacuo with toluene (3 X 50 mL), and 1.1 g title molecule is obtained with 90% HPLC purity and 73% yield.

Example 2: Preparation of Intermediate 2

[0046] The following compound is prepared:

Intermediate 2

[0047] 8-Hydroxyjulolidine (1.4 g, 7.2 mmol) and 4-formyl benzoic acid (500 mg, 3.6 mmol) are mixed with 60% aqueous sulfuric (40 mL) and stirred at 150° C for 24 hours under air atmosphere. The reaction mixture is added to ice (100 g), after which 60% NaOH is carefully added to pH 6-7, precipitating the crude product. The crude product is extracted between dichloromethane (DCM) and water. The organic phase is separated, and washed with brine. The organic solvent is removed and the final products are dried by evaporating with EtOH and toluene 5 times to yield 1.1 g product (61% yield). Purity as determined by HPLC is 100%. MS (ESI) [M+]=491.

Example 3: Preparation of Intermediate 3

[0048] The following compound is repared:

Intermediate 3

[0049] 8-Hydroxyjulolidine (1.4 g, 7.2 mmol) and 3-formyl benzoic acid (500 mg, 3.6 mmol) are mixed with 60% aqueous sulfuric (40 mL) and stirred at 150° C for 24 hours under air atmosphere. The reaction mixture is added to ice (100 g), after which 60% NaOH is carefully added to pH 6-7, precipitating the crude product. The crude product is extracted between DCM and water. The organic phase is separated, and washed with brine. The organic solvent is removed and the final products are dried by evaporating with EtOH and toluene 5 times to yield 1.7 g 3- acid product (94% yield). Purity as determined by HPLC is 95%. MS (ESI) [M+]=491.

Example 4: Preparation of Intermediate 4

[0050] The following compound is prepared:

Intermediate 4

[0051] 8-Hydroxyjulolidine (1.4 g, 7.2 mmol) and 4-bromobenzaldehyde (670 mg, 3.6 mmol) are mixed with 60% aqueous sulfuric (40 mL) and stirred at 150° C for 24 hours under air atmosphere. The reaction mixture is added to ice (100 g), after which 60% NaOH is carefully added to pH 6-7, precipitating the crude product and dried under vacuum overnight to 1.12 g black solid. The crude product is dissolved in 90/10 CHC1₃/ methanol (5 mL) and applied on to a column of silica (35x100 mm) and eluted with 10-18% methanol in CHC1₃. Pure fractions are pooled and the solvent is evaporated at reduced pressure to 448 mg product.

Example 5: Preparation of Intermediate 5

[0052] The following compound is prepared:

Intermediate 5

[0053] Intermediate 4 prepared as described in Example 4 (236 mg, 0.45 mmol) and tert- butyl N-{[4-(dihydroxyboranyl)phenyl]methyl}carbamate (225 mg, 0.90 mmol) are transferred to a 50 mL flask with ethanol and 2M K₂C0₃ aqueous solution (672 μί, 1.34 mmol) added. The reaction mixture is briefly degassed and [1,1 '- bis(diphenylphosphino)ferrocene]dichloropalladium(II). DCM (18 mg, 0.022 mmol)) is added, degassing again and stirred under nitrogen at room temperature. After 50 minutes of stirring, add more [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(II). DCM (13 mg, 0.016 mmol) is added and the mixture heated to 65° C for 1 hour. This is followed by evaporation and dissolution in DCM, addition of 4 g silica and evaporation and silica chromatography through a 12x2.5 cm column, packed with DCM, eluted with 5-20% methanol (MeOH) in DCM and evaporation of pure fraction gave 236 mg golden brown sticky solid with 90% HPLC purity.

Example 6: Preparation of a 2-sulforhodamine trifluoroacetate (Compound 1)

[0054] The following compound is prepared:

Compound 1

[0055] Compound 1 is 16-{2-[(6-aminohexyl)sulfamoyl]phenyl}-3-oxa- 9λ⁵,23- diazaheptacyclo[17.7.1.1⁵'⁹.0²'¹⁷.0⁴'¹⁵.0²³'²⁷.0¹³'²⁸]octacosa- 1(27),2(17),4,9(28),13,15,18- heptaen-9-ylium; 2,2,2-trifluoroacetate according to the nomenclature system that we use and is prepared as follows. Intermediate 1 (0.66 mmol, 350 mg) is dissolved in DCM (10 mL) and a drop of dimethylformamide (DMF). Oxalylchloride (3.98 mmol, 500 mg) is added and the reaction mixture is stirred at room temperature for one hour. An evolution of gas is immediately noted. The solvent is evaporated, mixed with toluene (10 mL) and reevaporated, the residue dissolved in DCM (12 mL), cooled in an ice bath, and divided into two equal portions. One portion is carefully (under 5 minutes) added to an ice cold solution of hexamethylenediamine (1.06 mmol, 120 mg) in DCM (5 mL) and triethylamine (0.40 mmol, 40 mg) in DCM (5 mL). The dark bluish solutions switch immediately to dark red. Reaction completes within 30 minutes. A part of the crude mixture is purified on preparative HPLC, ACE-C8 column with a methanol gradient in 0.1% TFA in water to give 58 mg (24%) of product as a dark blue copper shimmering glass. Purity as determined by HPLC is 100%. MS (ESI) [M+]=625. Absorbance max is 586 nm. Example 7: Preparation of a 2-sulforhodamine trifluoroacetate (Compound 2)

[0056] The following compound is prepared:

Compound 2

[0057] Compound 2 is 16-{2-[3-(aminomethyl)pyrrolidine-l- sulfonyl]phenyl}-3-oxa- 9 ⁵,23- diazaheptacyclo[17.7.1.1⁵'⁹.0²'¹⁷.0^4,15.0²³'²⁷.0¹³'²⁸]octacosa- l(27),2(17),4,9(28),13,15,18-heptaen-9-ylium; 2,2,2-trifluoroacetate according to the nomenclature system that we use and is prepared as follows. Intermediate 1 (0.66 mmol, 350 mg) is dissolved in DCM (10 mL) and a drop of DMF. Oxalylchloride (3.98 mmol, 500 mg) is added and the reaction mixture is stirred at room temperature for one hour. An evolution of gas is immediately noted. The solvent is evaporated, mixed with toluene (10 mL) and reevaporated, the residue dissolved in DCM (12 mL), cooled in an ice bath, divided into two equal portions. One portion is carefully (under 5 minutes) added to an ice cold solution of tert-butyl N-(pyrrolidin-3-ylmethyl)carbamate (1.06 mmol, 90 mg) in DCM (5 mL) and triethylamine (0.40 mmol, 40 mg) in DCM (5 mL). The dark bluish solutions switch immediately to dark red. Reaction completes within 30 minutes. TFA is added (1 mL in ca 2 mL of DCM), completes deprotection in one hour. A part of the crude is purified on preparative HPLC, ACE-C8 column with a methanol gradient in 0.1% TFA in water to give 95 mg (39%) as a dark blue copper shimmering glass. Purity as determined by HPLC is 100%. MS (ESI) [M+]=605. Absorbance max is 590 nm. Example 8: Preparation of a 4-carboxrhodamine trifluoroaceate (Compound 3)

[0058] The following compound is repared:

Compound 3

[0059] Compound 3 is 16-{4-[(2-aminoethyl)carbamoyl]phenyl}-3-oxa- 9λ⁵,23- diazaheptacyclo[17.7.1.1^5,9.0²'¹⁷.0⁴'¹⁵.0²³'²⁷.0¹³'²⁸]octacosa- 1(27),2(17),4,9(28),13,15,18- heptaen-9-ylium; 2,2,2-trifluoroacetate according to the nomenclature system that we use and is prepared as follows. Intermediate 2 (150 mg, 0.31 mmol) is dissolved in DMF-CH₃CN (1- 4, 7 mL). Triethylamine (94 mg, 0.93 mmol) and 2,4,6-tripropyl-l,3,5,2,4,6- trioxatriphosphorinane-2,4,6-trioxide solution in ethyl acetate (592 μΐ., 0.93 mmol) are added and the mixture stirred at room temperature for 15 minutes. A 1/6-part is taken out and added to 1,2-diaminoethane (19 mg, 0.31 mmol) and the reaction mixture stirred at room

temperature for 1.5 hours. Purification is preformed on preparative HPLC, ACE-C8 column with a methanol gradient in 0.1% TFA in water to give 24 mg (72%) as a dark blue black glass. Purity as determined by HPLC is 93%. MS (ESI) [M+]=533. Absorbance max is 586 nm.

Example 9: Preparation of a 4-carboxrhodamine trifluoroaceate (Compound 4)

[0060] The following compound is prepared:

Compound 4

[0061] Compound 4 is 16-{4-[(3-aminopropyl)carbamoyl]phenyl}-3-oxa- 9λ⁵,23- diazaheptacyclo[17.7.1.1⁵'⁹.0²'¹⁷.0^4,15.0²³'²⁷.0¹³'²⁸]octacosa- 1(27),2(17),4,9(28),13,15,18- heptaen-9-ylium; 2,2,2-trifluoroacetate according to the nomenclature system that we use and is prepared using the same procedure as used for preparing Compound 3, but with 1,3- diaminopropane replacing 1,2-diaminoethane (23 mg, 0.31 mmol) to obtain 25 mg (73% yield) product. Purity as determined by HPLC is 100%. MS (ESI) [M+]=547. Absorbance max is 584 nm.

Example 10: Preparation of a 4-carboxrhodamine trifluoroaceate (Compound 5)

[0062] The following compound is prepared:

Compound 5

[0063] Compound 5 is 16-{4-[(2,2-dimethoxyethyl)carbamoyl]phenyl}-3-oxa- 9λ⁵,23- diazaheptacyclo[17.7.1.1⁵'⁹.0²'¹⁷.0⁴'¹⁵.0^23>27.0¹³'²⁸]octacosa- 1(27),2(17),4,9(28),13,15,18- heptaen-9-ylium; 2,2,2-trifluoroacetate according to the nomenclature system that we use and is prepared using the same procedure as used for preparing Compound 3, but with 2,2- dimethoxyethan-1 -amine replacing 1,2-diaminoethane (33 mg, 0.31 mmol) to obtain 26 mg (73% yield) product. Purity as determined by HPLC is 100%. MS (ESI) [M+]=578.

Absorbance max is 584 nm.

Example 11 : Preparation of a 4-carboxrhodamine trifluoroaceate (Compound 6)

[0064] The following compound is prepared:

Compound 6

[0065] Compound 6 is 16- {4-[(6-aminohexyl)carbamoyl]phenyl}-3-oxa- 9λ⁵,23- diazaheptacyclo[17.7.1.1⁵'⁹.0²'¹⁷.0⁴'¹⁵.0²³'²⁷.0^13,28]octacosa- 1(27),2(17),4,9(28),13,15,18- heptaen-9-ylium; 2,2,2-trifluoroacetate according to the nomenclature system that we use and is prepared using the same procedure as used for preparing Compound 3, but with 1,6- diaminohexane replacing 1,2-diaminoethane (36 mg, 0.31 mmol) to obtain 32 mg (88% yield) product. Purity as determined by HPLC is 100%. MS (ESI) [M+]=589. Absorbance max is 586 nm.

Example 12: Preparation of a 4-carboxrhodamine trifluoroaceate (Compound 7)

[0066] The following compound is prepared:

Compound 7 [0067] Compound 7 is 16-[4-({[4- (aminomethyl)phenyl]methyl}carbamoyl)phenyl]-3- oxa-^⁵,23- diazaheptacyclo[17.7.1.1⁵'⁹.0^2,17.0⁴'¹⁵.0²³'²⁷.0¹³'²⁸]octacosa- l(27),2(17),4,9(28),13,15,18-heptaen-9-ylium; 2,2,2-trifluoroacetate according to the nomenclature system that we use and is prepared using the same procedure as used for preparing Compound 3, but with [4-(aminomethyl)phenyl]methanamine replacing 1,2- diaminoethane (42 mg, 0.31 mmol) to obtain 36 mg (96% yield) product. Purity as determined by HPLC is 99%. MS (ESI) [M+]=609. Absorbance max is 590 nm.

Example 13: Preparation of a 4-carboxrhodamine trifluoroaceate (Compound 8)

[0068] The following compound is prepared:

Compound 8

[0069] Compound 8 is 16-{4-[(4-oxopiperidin-l-yl)carbonyl]phenyl}-3-oxa- 9λ⁵,23- diazaheptacyclo[17.7.1.1⁵'⁹.0²'¹⁷.0⁴'¹⁵.0²³' ⁷.0¹³'²⁸]octacosa- 1 (27),2( 17),4,9(28), 13,15,18- heptaen-9-ylium; 2,2,2-trifluoroacetate according to the nomenclature system that we use and is prepared using the same procedure as used for Compound 3, but with piperidin-4-one replacing 1,2-diaminoethane (31 mg, 0.31 mmol) to obtain 28 mg (79% yield) product. Purity as determined by HPLC is 82%. MS (ESI) [M+]=572. Absorbance is max 588 nm.

Example 14: Preparation of a 3-carboxrhodamine trifluoroaceate (Compound 9

[0070] The following com ound is prepared:

Compound 9

[0071] Compound 9 is 16-{3-[(2-aminoethyl)carbamoyl]phenyl}-3-oxa- 9λ⁵,23- diazaheptacyclo[17.7.1.1^5,9.0²'¹⁷.0⁴'¹⁵.0²³'²⁷.0¹³'²⁸]octacosa- 1(27),2(17),4,9(28),13,15,18- heptaen-9-ylium; 2,2,2-trifluoroacetate according to the nomenclature system that we use and is prepared using the same procedure as used for Compound 3, but with Intermediate 3 replacing 1,2-diaminoethane as acid and 1,2-diaminoethane (19 mg, 0.31 mmol) as amine to obtain 20 mg (60% yield) product. Purity as determined by HPLC is 100%. MS (ESI)

[M+]=533. Absorbance max is 586 ran.

Example 15: Preparation of a 3-carboxrhodamine trifluoroaceate (Compound 10)

[0072] The following compound is prepared:

Compound 10

[0073] Compound 10 is 16-{3-[(3-aminopropyl)carbamoyl]phenyl}-3-oxa- 9λ⁵,23- diazaheptacyclo[17.7.1.1⁵'⁹.0²'¹⁷.0⁴'¹⁵.0²³'²⁷.0¹³'²⁸]octacosa- 1(27),2(17),4,9(28),13,15,18- heptaen-9-ylium; 2,2,2-trifluoroacetate according to the nomenclature system that we use and is prepared using the same procedure as used for preparing Compound 9, but with 1,3- diaminopropane replacing 1,2-diaminoethane (23 mg, 0.31 mmol) to obtain 19 mg (56% yield) product. Purity as determined by HPLC is 100%. MS (ESI) [M+]=547. Absorbance max is 584 nm.

Example 16: Preparation of a 3-carboxrhodamine trifluoroaceate (Compound 11

[0074] The following com ound is prepared:

Compound 1 1

[0075] Compound 11 is 16- {3-[(6-aminohexyl)carbamoyl]phenyl}-3-oxa-9 ⁵,23- diazaheptacyclo[17.7.1.1^5,9.0²'¹⁷.0⁴'¹⁵.0²³'²⁷.0¹³'²⁸]octacosa- 1 (27),2(17),4,9(28), 13,15,18- heptaen-9-ylium; 2,2,2-trifluoroacetate according to the nomenclature system that we use and is prepared using the same procedure as used for preparing Compound 9, but with 1 ,6- diaminohexane replacing 1,2-diaminoethane (36 mg, 0.31 mmol) to obtain 27 mg (74% yield) product. Purity as determined by HPLC is 100%. MS (ESI) [M+]=589. Absorbance max is 584 nm.

Example 17: Preparation of a 3-carboxrhodamine trifluoroaceate (Compound 12)

[0076] The following compound is prepared:

Compound 12

[0077] Compound 12 is 16-[3-({[4- (aminomethyl)phenyl]methyl}carbamoyl)phenyl]-3- oxa-9 ⁵,23- diazaheptacyclo[17.7.1.1⁵'⁹.0^2,17.0^4,15.0²³'²⁷.0¹³'²⁸]octacosa- l(27),2(17),4,9(28),13,15,18-heptaen-9-ylium; 2,2,2-trifluoroacetate according to the nomenclature system that we use and is prepared using the same procedure is as used for preparing Compound 9, but with [4-(aminomethyl)phenyl]methanamine replacing 1,2- diaminoethane (42 mg, 0.31 mmol) to obtain 32 mg (86% yield) product. Purity as determined by HPLC is 100%. MS (ESI) [M+]=609. Absorbance max is 587 nm.

Example 18: Preparation of a 3-carboxrhodamine trifluoroaceate (Compound 13)

[0078] The following compound is prepared:

Compound 13

[0079] Compound 13 is 16-{3-[(4-oxopiperidin-l-yl)carbonyl]phenyl}-3-oxa- 9λ⁵,23- diazaheptacyclo[17.7.1.1⁵'⁹.0²'¹⁷.0⁴'¹⁵.0²³'²⁷.0¹³'²⁸]octacosa- 1(27),2(17),4,9(28),13,15,18- heptaen-9-ylium; 2,2,2-trifluoroacetate according to the nomenclature system that we use and is prepared using the same procedure as used for preparing Compound 9, but with piperidin- 4-one replacing 1,2-diaminoethane (31 mg, 0.31 mmol) to obtain 34 mg (96% yield) product. Purity as determined by HPLC is 80%. MS (ESI) [M+]=572. Absorbance max is 584 nm.

Example 19: Preparation of a 3-carboxrhodamine trifluoroaceate (Compound 14)

[0080] The following compound is prepared:

Compound 14

[0081] Compound 14 is 16-{3-[(2,2-dimethoxyethyl)carbamoyl]phenyl}-3-oxa-9 ⁵,23- diazaheptacyclo[17.7.1.1⁵'⁹.0²'¹⁷.0⁴'¹⁵.0²³'²⁷.0¹³'²⁸]octacosa- 1(27),2(17),4,9(28),13,15,18- heptaen-9-ylium; 2,2,2-trifluoroacetate according to the nomenclature system that we use and is prepared using the same procedure is as used for preparing Compound 9, but with 2,2- dimethoxyethan-1 -amine replacing 1,2-diaminoethane (33 mg, 0.31 mmol) to obtain 29 mg (81% yield) product. Purity as determined by HPLC is 98%. MS (ESI) [M+]=578.

Absorbance max is 588 nm.

Example 20: Preparation of a 4-carboxrhodamine trifluoroaceate (Compound 15)

[0082] The following compound is prepared:

Compound 15 [0083] Compound 15 is 16- {4-[4-(aminomethyl)phenyl]phenyl} -3-οχα-9λ⁵,23- diazaheptacyclo[17.7.1.1⁵'⁹.0²'¹⁷.0⁴'¹⁵.0²³'²⁷.0¹³'²⁸]octacosa- 1(27),2(17),4,9(28),13,15,18- heptaen-9-ylium; 2,2,2-trifluoroacetate according to the nomenclature system that we use and is prepared as follows. Intermediate 5 (236 mg, 0.35 mmol) is dissolved in 4 mL DCM/TFA (3/1). After 30 minutes, the solvent is blown off with air. The crude product is purified on an ACE-C8 (150x30 mm) column eluting with 20-100% methanol in 0.1% TFA. Pure fractions are evaporated to 115 mg (% yield) deep blue/red solid with a green tinge. Purity as determined by HPLC is 98%. MS (ESI) [M+]=552. Absorbance max is 578 nm.

Example 21: Preparation of a 4-carboxrhodamine trifluoroaceate (Compound 16)

[0084] The following compound is prepared:

Compound 16

[0085] Compound 16 is 16-[4-(2-amino-4-methylphenyl)phenyl]-3-oxa-9 ⁵,23- diazaheptacyclo[17.7.1.1⁵'⁹.0²'¹⁷.0⁴'¹⁵.0²³'²⁷.0¹³'²⁸]octacosa- 1(27),2(17),4,9(28),13,15,18- heptaen-9-ylium; 2,2,2-trifluoroacetate according to the nomenclature system that we use and is prepared as follows. Intermediate 4 (152 mg, 0.29 mmol) and 5-methyl-2-(4 ,4,5,5- tetramethyl)-(l,3,2-dioxaborolan-2-yl)-phenylamine (135 mg, 0.58 mmol) are dissolved in ethanol (10 mL) and treated with 2M K₂C0₃ (434 μΐ., 0.87 mmol) and [1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium(II)DCM (11 mg, 0.015 mmol). The reaction mixture is heated at 65° C for 1 hour. The crude product is filtered through celite and purified on an ACE-C8 (150x30 mm) column eluting with 60-100% methanol in 0.1% TFA, evaporating pure fractions to 80 mg (50% yield) deep blue/red solid with a green tinge. Purity as determined by HPLC is 90%. MS (ESI) [M+]=552. Absorbance max is 580 nm. Example 22: Preparation of a 4-carboxrhodamine trifluoroaceate (Compound 17)

[0086] The following compound is prepared:

Compound 17

[0087] Compound 17 is 16-[4-(4-acetylphenyl)phenyl]-3-oxa-9 ⁵,23- diazaheptacyclo[ 17.7.1.1⁵'⁹.0²'¹⁷.0⁴'¹⁵.0²³'²⁷.0¹³'²⁸]octacosa- 1 (27),2(17) ,4,9(28), 13,15,18- heptaen-9-ylium; 2,2,2-trifluoroacetate according to the nomenclature system that we use and is prepared as follows. Intermediate 4 (152 mg, 0.29 mmol) and 4-ethanone phenyl boronic acid (95 mg, 0.58 mmol) are dissolved in ethanol (10 mL) and treated with 2M K₂C0₃ (434 μΕ, 0.87 mmol) and [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(II).DCM (11 mg, 0.015 mmol). The reaction mixture is heated at 65° C for 1 hour. The crude product is filtered through celite and purified on an ACE-C8 (150x30 mm) column eluting with 60- 100% methanol in 0.1% TFA, evaporating pure fractions to 54 mg (33% yield) deep blue/red solid with a green tinge. Purity as determined by HPLC is 92%. MS (ESI) [M+]=565. Absorbance max is 580 nm.

Example 23: Preparation, Purification and Crystallization of a 2-sulforhodamine dichloride (Compound 18)

[0088] The following compound is prepared:

Compound 18

[0089] Compound 18 is 16-{2-[(6-aminohexyl)sulfamoyl]phenyl}-3-oxa- 9λ⁵,23- diazaheptacyclo[17.7.1.1⁵'⁹.0²'¹⁷.0⁴'¹⁵.0²³'²⁷.0¹³'²⁸]octacosa- 1(27),2(17),4,9(28),13, 15,18- heptaen-9-ylium; dichloride according to the nomenclture system that we use and is prepared as follows.

[0090] Synthetic Step 1 : A mixture of 8-hydroxyjulolidine (200g) and sodium 2- formylbenzene-1 -sulfonate (HOg) is added to 1.8L of 60% H2S04 aqueous pre-warmed at 150 °C and stirred for 4 hours. After the reaction is finished monitored by LC-MS, the reaction mixture is cooled to 0 °C. 60% of sodium hydroxide (aqueous) is added slowly, until pH value of the reaction mixture to 2 (product is precipitated). Celite (800 g) is added to the reaction mixture with precipitated raw product and the reaction mixture is filtered. The resulting solid with celite is washed with toluene (3X500 mL) and added to anhydrous ethanol (4 L) and heated with stiring at 60 °C for 0.5 hour. The reaction mixture then is filtered. The filtrate is concentrated under vacuum and then co-evaporated with toluene to get rid of traces of water and to get crude Rhodamine sulfonic acid intermediate (270g) as a dark blue solid.

[0091] Synthetic Step 2: Crude Rhodamine sulfonic acid intermediate from Step 1 (100 g, 0.19 mol) is dissolved in a mixture of solvents dichloromethane (500 mL) and DMF (13.9 g). The reaction solution is cooled to 0 °C and oxalyl chloride (48.1 g, 0.379 mol) is added dropwise. The reaction mixture is stirred for additional 2 hours at 0 °C. The reaction mixture is then concentrated in vacuum and to the resulting residue is four iterations of adding toulene (100 mL) and evaporation performed. The crude Rhodamine sulfonic acid chloride intermediate is used directly in next step after drying under reduced pressure for 6h.

[0092] Synthetic Step 3: A solution of hexane-l,6-diamine (176 g, 1.52 mol) in dichloromethane (800 mL) is cooled to 0 °C. A solution of all crude Rhodamine sulfonic acid chloride intermediate obtained in Step 2 in dichloromethane (500 mL) is added dropwise with continued cooling to 0 °C. The reaction mixture is stirred for an additional 4 hours at 0 °C. After controlling with thin layer chromatography (TLC) that the reaction is complete, the reaction mixture is quenched by a filtration through celite-paper, and evaporating the filtrate in vacuum four times with additions of toluene (150 mL) each time. The resulting solid is dried under reduced pressure.

[0093] Purification: Purification by chromatography through silica gel is carried out using a mixture of solvents dichloromethane and MeOH (gradient from 15:1 to 1:1), saturated with HC1 gas. A second silica gel chromatography yields 12.5 g of the 2-sulforhodamine dichloride (Compound 18) as a green-black solid (purity >98% by HPLC). The total yield for 3 all steps is 11.0%.

[0094] Crystallization: 2.5 g of the 2-sulforhodamine dichloride (Compound 18) of approx 88% purity is dissolved in ethanol (approx 50 mL) and ethyl acetate (approx 150 mL) is added, which precipitates a sticky solid. The supernatant is treated with silica gel (5 g) and filtered. The silica is leached with 1 M HC1 (200 mL), the resulting purple solution is then used to dissolve the sticky solid that is precipitated with ethyl acetate in a previous step. The solution is heated close to boiling and treated with warm brine (400 mL, aq NaCl saturated at room temperature). The solution is allowed to cool to room temperature and minor precipitation is observed. pH is adjusted from -0.2 to +0.3 by careful addition of solid NaHC0₃. The mixture is heated to boiling, a cooled aliquot of the solution is analyzed to pH 0.0. Solid NaHC0₃ is added to the warm solution until a cooled sample showed pH 0.1. The suspension is allowed to cool to room temperature, after two days the supernatant is analyzed to pH 0.0. Solid NaHC0₃ is carefully added to the mixture without any more precipitation being observed (use a red lamp!). The solid is separated with centrifugation and the supernatant discarded (pH 0.0). The solid is suspended in the same volume of 20% aq NaCl that is used in the previous precipitation and centrifuged, discarding the supernatant (pH 0.5). The solid is again suspended in an equal volume, centrifuged and the supernatant discarded (pH 0.55). The second supernatant is not colorless and the washing procedure halted. The solid is dried in vacuum oven to 1.8 g of golden-green material, 96% purity with Syntagon's HPLC method. The above crystallization process can be used with an acetate salt of the 2- sulforhodamine (such as the trifluoroaceate salt as in Compound 1) instead of the dichloride salt of Compound 18. [0095] FIG. 6 is a UV absorption spectrum of Compound 18 scanning from 200 nm to 800 nm at a scan speed of 400 nm/minute. The maximum UV absorption is at 586 nm. FIG. 7 is a fluorescence emission scan and FIG. 8 is a fluorescence excitation scan of Compound 18. FIG. 9 is a 3 -dimensional fluorescence scan of Compound 18 wherein EM is the emission wavelength and EX is the excitation wavelength. The Excitation (max), which is the maximum absorbance wavelength, is 566 nm and the Emission (max), which is the wavelength with maximum emission intensity, is 618 nm.

Example 24: Rearrangement of Compound 18 to form an isomer (Compound 19)

[0096] The following com ound is prepared:

Compound 19

[0097] Compound 18 can undergo a re- arrangement to form an isomer Compound 19, which can be used like its parent compound Compound 18 and the other novel rhodamine dyes of the present invention in forming conjugates with other molecules, such as macromolecules, to form single isomeric conjugation products. Compound 19 is 16-[N-(6- azaniumylhexyl)benzenesulfonamido]-3-oxa- 9λ⁵,23- diazaheptacyclo[17.7.1.1^5,9.0²'¹⁷.0⁴'¹⁵.0^23,27.0¹³'²⁸]octacosa-l(27),2(17),4,9(28),13,15,18- heptaen-9-ylium; dichloride according to the nomenclature system that we use and is prepared as follows. Compound 18 as the dichloride salt (1.16 g, 1.6 mmol) is dissolved in methanol (30 mL). Aqueous sodium hydroxide (1.0 M, 16 mL) is added drop-wise to the 2- SHR solution at room temperature. The resulting colorless solution is stirred for 30 min at room temperature and then evaporated with ethanol (10 mL) and toluene (10 mL) to a colorless solid. The solid is dissolved in methanol (20 mL) and aqueous hydrochloric acid (1.0 M, 16 mL) is added, which reforms the deep red color. The mixture is evaporated and the solid residue purified with silica chromatography, eluting with methanol (10%-12.5%) in chloroform containing 0.1% concentrated hydrochloric acid. Selected pure fractions are evaporated with ethanol and toluene, drying at high vacuum overnight results in 120 mg 2- SHR-iso (11% yield) as a metallic green solid. Purity as determined by HPLC is 97.8%. MS (ESI) [M+]=625. Absorbance max is 586 nm.

[0098] Similarly, Compound 1 or any other salt of the 2-sulforhodamine can undergo the same re- arrangement as Compound 18 to form the corresponding isomeric product with the corresponding salt.

Example 25: Synthesis of conjugate with Compound 15 and carboxymethylated-dextran (CM-dextran)

[0099] To a solution of Compound 15 (Mw: 665.77 g/mol, n: 0.038 mmol, m: 25 mg) dissolved in dimethyl sulfoxide (DMSO) (3 ml) is added cold acetaldehyde from a stock solution (118 μΐ) with stirring. After 15 minutes a solution of CM-dextran 150 (300 mg) in distilled water (3 ml) is added with rapid stirring, followed by cyclohexyl-isonitrile (Mw: 109.1 g/mol, n: 0.21 mmol, m: 22.9 mg, δ: 0.878g ml, V: 26.5 μΐ). The pH is adjusted to 5.9 with a few drops of 1M aq. HC1. The reaction mixture is left with stirring for four hours.

[0100] After four hours the pH has increased to 6.02. Ethanolamine (Mw: 61.08 g mol, n: 3.34 mmol, m: 0.204 g, δ: 1.02, V: 200 μΐ) is added and the reaction is left for 90 minutes with stirring.

[0101] Ninety minutes after the addition of ethanolamine the pH has increased to 11.2. After addition of saturated sodium chloride (0.5 ml), the reaction mixture is slowly poured in to ethanol (96%, 50 ml) with rapid stirring where after the precipitated blue solid is allowed to settle overnight. The supernatant is decanted and the residue is filtered on a glass filter funnel (p3). The precipitate is washed with Ethanol (3x10 ml) and filtered. The product is reprecipitated until free from unreacted dye. It is dried in vacuo at 60° C for 15 hours. Yield is 225 mg.

[0102] Excitation (max) is 587 nm; Emission(max) is 608.

Example 26: Synthesis of conjugate with Compound 18 with CM-dextran

[0103] To a solution of Compound 18 (chloride salt, Mw: 697.7 g/mol, n: 0.136 mmol, m: 95.4 mg) dissolved in DMSO (14 mL) is added cold acetaldehyde from a stock solution

(391 μί,) with stirring. After 15 minutes a solution of CM-dextran 150 (1.8 g) in distilled water (19.2 mL) is added with rapid stirring, followed by cyclohexyl- isonitrile (Mw: 109.1 g/mol, n: 1.4 mmol, m: 152.6 mg, δ: 0.878g/mL, V: 172 μΐ). The pH is adjusted to 5 with a few drops of 1M aq. HC1. The reaction mixture is left with stirring overnight.

[0104] Ethanolamine (Mw: 61.08 g/mol, n: 6.64 mmol, m: 0.40 g, δ: 1.02, V: 400 μί) is added and the reaction is left for 60 minutes with stirring. [0105] Ninety minutes after the addition of ethanolamine the pH has increased to 11.2. After addition of saturated sodium chloride (0.5 ml), the reaction mixture is slowly poured in to ethanol (96%, 50 ml) with rapid stirring where after the precipitated blue solid is allowed to settle overnight.

[0106] The supernatant is decanted and the residue is filtered on a glass filter funnel (p3). The precipitate is washed with ethanol (3 10 ml) and filtered. The product is reprecipitated until free from unreacted dye. It is dried in vacuo at 60° C for 15 hours. Yield is 1.3 g.

[0107] FIG. 10 is a UV absorption spectrum of the conjugate scanning from 200 nm to 800 nm at a scan speed of 400 nm/minute. The maximum UV absorption is at 589.5 nm. FIG. 11 is a fluorescence emission scan and FIG. 12 is a fluorescence excitation scan of the conjugate. FIG. 13 is a 3-dimensional fluorescence scan of the conjugate wherein EM is the emission wavelength and EX is the excitation wavelength.

[0108] Excitation (max) is 589 nm ; Emission(max) is 608 nm.

Example 27: Synthesis of conjugate with Compound 3 with CM-dextran

[0109] To a solution of Compound 3 (TFA salt, Mw: 646.7 g/mol, n: 0.037 rrrmol, m: 24 mg) dissolved in DMSO (3 mL) is added cold acetaldehyde from a stock solution (118 μί) with stirring. After 15 minutes a solution of CM-dextran 150 (300 mg) in distilled water (3 mL) is added with rapid stirring, followed by cyclohexyl- isonitrile (Mw: 109.1 g/mol, n: 0.21 mmol, m: 22.9 mg, δ: 0.878g/mL, V: 26.5 μί). The pH is adjusted to 5 with a few drops of 1M aq. HC1. The reaction mixture is left with stirring for 4 hours.

[0110] Ethanolamine (Mw: 61.08 g/mol, n: 6.64 mmol, m: 0.20 g, δ: 1.02, V: 200 μΐ.) is added and the reaction is left for 60 minutes with stirring. The reaction product, after addition of saturated sodium chloride (0.5 ml), is slowly poured into ethanol (96%, 50 ml) with rapid stirring whereafter the precipitated blue solid is allowed to settle overnight.

[0111] The supernatant is decanted and the residue is filtered on a glass filter funnel (p3). The precipitate is washed with ethanol (3x10 ml) and filtered. The product is reprecipitated until free from unreacted dye. It is dried in vacuo at 60° C for 15 hours. Yield is 339 mg.

[0112] Excitation (max) is 588 nm ; Emission(max) is 609 nm.

Example 28: Synthesis of conjugate with Compound 16 with CM-dextran

[0113] To a solution of Compound 16 (TFA salt, Mw: 665.7 g/mol, n: 0.038 mmol, m: 25 mg) dissolved in DMSO (3 mL) is added cold acetaldehyde from a stock solution (118 μΕ) with stirring. After 15 minutes a solution of CM-dextran 150 (300 mg) in distilled water (3 mL) is added with rapid stirring, followed by cyclohexyl- isonitrile (Mw: 109.1 g/mol, n: 0.21 mniol, m: 22.9 mg, δ: 0.878g/mL, V: 26.5 μί). The pH is adjusted to 5 with a few drops of 1M aq. HC1. The reaction mixture is left with stirring for 4 hours.

[0114] Ethanolamine (Mw: 61.08 g/mol, n: 6.64 mmol, m: 0.20 g, δ: 1.02, V: 200 μ ) is added and the reaction is left for 60 minutes with stirring. The reaction product, after addition of saturated sodium chloride (0.5 ml), is slowly poured into ethanol (96%, 50 ml) with rapid stirring where after the precipitated blue solid is allowed to settle overnight. The supernatant is decanted and the residue is filtered on a glass filter funnel (p3). The precipitate is washed with ethanol (3x10 ml) and filtered. The product is reprecipitated until free from unreacted dye. It is dried in vacuo at 60° C for 15 hours. Yield is 167 mg.

[0115] Excitation (max) is 585 nm; Emission(max) is 606 nm.

REFERENCES

1. Lee S, McAuliffe DJ, Kodama T, Doukas AG, In vivo transdermal delivery using a shock tube, Shock Waves (2000) 10:307-307

2. Janson LW, Ragsdale K, Luby-Phelps K, Mechanism and size cutoff for steric exclusion from actin-rich cytoplasmic domains., Biophys J (1996) 71:1228-1234

3. Pu R, Robinson KR, Cytoplasmic calcium gradients and calmodulin in the early development of the fucoid alga Pelvetia compressa., J Cell Sci (1998) 111 ( Pt 21):3197-3207

4. Nishiya T, Kajita E, Horinouchi T, Nishimoto A, Miwa S, Distinct roles of TIR and non-TIR regions in the subcellular localization and signaling properties of MyD88, FEBS Lett (2007) 581:3223-3229

5. Tanner GA, Sandoval RM, Dunn KW, Two-photon in vivo microscopy of sulfonefluorescein secretion in normal and cystic rat kidneys, Am J Physiol Renal Physiol (2004) 286:F152-F160

6. Titus JA, Haugland R, Sharrow SO, Segal DM, Texas Red, a hydrophilic, red- emitting fluorophore for use with fluorescein in dual parameter flow microfluorometric and fluorescence microscopic studies, J. Immunol. Methods (1982) 50 (2): 193-204

7. Nimmerjahn, A., Kirchhoff, F., Kerr, J.N., Helmchen, F., Sulforhodamine 101 as a specific marker of astroglia in the neocortex in vivo, Nature Methods (2004) 1: 31-7

8. Kim, T. G.; Castro, J. C; Loudet, A.; Jiao, J. G.-S.; Hochstrasser, R. M.; Burgess, K.; Topp, M. R., Journal of Physical Chemistry A (2006), 110(1), 20-27

Claims

CLAIMS We claim:

1. A composition comprising a novel rhodamine dye or a salt thereof, wherein the rhodamine dye contains only one single functional group and wherein the rhodamine dye is capable of conjugating with another molecule via the functional group to form a single isomeric conjugation product.

2. The composition of claim 1 wherein the novel rhodamine dye contains a julolidine structure element.

3. The composition of claim 1 wherein the functional group is selected from the group consisting of amines, alcohols, isocyanates, isothiocyanates, thiols, and carboxylic acids.

4. The composition of claim 1 wherein the other molecule is a macromolecule.

5. The composition of claim 4 wherein the macromeolecule is selected from the group consisting of polymers, proteins, dextrans, celluloses, carbohydrates, lipids and nucleic acids.

6. The composition of claim 5 wherein the protein is an antibody.

7. The composition of claim 5 wherein the nucleic acid is a DNA or an RNA.

8. The composition of claim 1 wherein the salt is selected from the group consisiting of trifluoroacetate, chloride, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzensulfonate and p-toluenesulfonate.

9. The composition of claim 1 wherein the salt is trifluoroacetate or chloride.

10. The composition of claim 1 wherein the salt is a pharmaceutically acceptable salt.

11. A composition comprising a novel rhodamine dye or a salt thereof with the general structure of

wherein Rl, R2, R3, R4 and R5 can be H or any group, and wherein only one of Rl, R2, R3, R4 or R5 contains a single functional group, and wherein the rhodamine dye is capable of conjugating with another molecule via the functional group to form a single isomeric conjugation product.

12. A composition comprising a novel rhodamine dye having a single functional group with a general formula of

/

or

wherein Ar is an aryl group, and Rl and/or R2 form a spacer which contains a single functional group on either Rl or R2 suitable for conjugation with anpother molecule.

13. The composition of claim 12 wherein the functional group is selected from the group consisting of amines, isocyanates, isothiocyanates, thiols, and carboxylic acids.

14. The composition of claim 12 wherein the rhodamine dye is in the form of a salt.

15. The composition of claim 14 wherein the salt is selected from the group consisiting of trifluoroacetate, chloride, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzensulfonate and p-toluenesulfonate.

16. The composition of claim 14 wherein the salt is trifluoroacetate or chloride.

17. The composition of claim 14 wherein the salt is a pharmaceutically acceptable salt.

18. The composition of claim 12 wherein the spacer is selected from the group consisting of hydrogen, alkyl, aryl, amide, alkyl sulfonamide, alkyl ether and alkyl amide.

The composition of claim 18 wherein the alkyl groups have a carbon chain length of 1 to 20.

20. The composition of claim 12 wherein Rl and R2 are connected to form a cyclic structure.

21. The composition of claim 20 wherein the cyclic structure is

or

22. The composition of claim 12 wherein the rhodamine dye having the structure of

23. The composition of claim 22 wherein the rhodamine dye is a salt.

24. The composition of claim 23 wherein the salt is selected from the group consisiting of trifluoroacetate, chloride, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotmate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzensulfonate and p-toluenesulfonate.

25. The composition of claim 23 wherein the salt is trifluoroacetate or chloride.

26. The composition of claim 23 wherein the salt is a pharmaceutically acceptable salt.

27. The composition of claim 22 undergoing a re-arrangement to form an isomer having the structure of

28. The composition of claim 27 wherein the rhodamine dye is a salt.

29. The composition of claim 28 wherein the salt is dichloride.

30. The composition comprising of claim 27, wherein the rhodamine dye is capable of conjugating with another molecule via the amino functional group to form a single isomeric conjugation product.

31. The composition of claim 30 wherein the other molecule is a macromolecule.

32. The composition of claim 31 wherein the macromeolecule is selected from the group consisting of polymers, proteins, dextrans, celluloses, carbohydrates, lipids and nucleic acids.

33. The composition of claim 32 wherein the protein is an antibody.

34. The composition of claim 32 wherein the nucleic acid is a DNA or an RNA.

The composition of claim 12 wherein the rhodamine dye having the structure of

36. The composition of claim 35 wherein the rhodamine dye is a salt.

37. The composition of claim 36 wherein the salt selected from the group consisiting of trifluoroacetate, chloride, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzensulfonate and p-toluenesulfonate.

38. The composition of claim 36 wherein the salt is trifluoroacetate.

39. The composition of claim 36 wherein the salt is a pharmaceutically acceptable salt.

40. The composition of claim 12 wherein the rhodamine dye having the structure of

41. The composition of claim 40 wherein the rhodamine dye is a salt.

42. The composition of claim 41 wherein the salt is selected from the group consisiting of trifluoroacetate, chloride, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzensulfonate and p-toluenesulfonate.

43. The composition of claim 41 wherein the salt is trifluoroacetate.

The composition of claim 41 wherein the salt is a pharmaceutically acceptable salt.

45. The composition of claim 12 wherein the rhodamine dye having the structure of

46. The composition of claim 45 wherein the rhodamine dye is a salt.

47. The composition of claim 46 wherein the salt selected from the group consisiting of trifluoroacetate, chloride, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzensulfonate and p-toluenesulfonate.

48. The composition of claim 46 wherein the salt is trifluoroacetate.

49. The composition of claim 46 wherein the salt is a pharmaceutically acceptable salt.

50. The composition of claim 12 wherein the rhodamine dye having the structure of

51. The composition of claim 50 wherein the rhodamine dye is a salt.

52. The composition of claim 51 wherein the salt is selected from the group consisiting of trifluoroacetate, chloride, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzensulfonate and p-toluenesulfonate.

53. The composition of claim 51 wherein the salt is trifluoroacetate.

54. The composition of claim 51 wherein the salt is a pharmaceutically acceptable salt.

55. The composition of claim 12 wherein the rhodamine dye having the structure of

56. The composition of claim 55 wherein the rhodamine dye is a salt.

57. The composition of claim 56 wherein the salt is selected from the group consisiting of trifluoroacetate, chloride, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzensulfonate and p-toluenesulfonate.

58. The composition of claim 56 wherein the salt is trifluoroacetate.

59. The composition of claim 56 wherein the salt is a pharmaceutically acceptable salt.

60. The composition of claim 12 wherein the rhodamine dye having the structure of

61. The composition of claim 60 wherein the rhodamine dye is a salt.

62. The composition of claim 61 wherein the salt is selected from the group consisiting of trifluoroacetate, chloride, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzensulfonate and p-toluenesulfonate.

63. The composition of claim 61 wherein the salt is trifluoroacetate.

64. The composition of claim 61 wherein the salt is a pharmaceutically acceptable salt.

The composition of claim 12 wherein the rhodamine dye having the structure of

66. The composition of claim 65 wherein the rhodamine dye is a salt.

67. The composition of claim 66 wherein the salt is selected from the group consisiting of trifluoroacetate, chloride, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzensulfonate and p-toluenesulfonate.

68. The composition of claim 66 wherein the salt is trifluoroacetate.

69. The composition of claim 66 wherein the salt is a pharmaceutically acceptable salt.

70. The composition of claim 12 wherein the rhodamine dye having the structure of

71. The composition of claim 70 wherein the rhodamine dye is a salt.

72. The composition of claim 71 wherein the salt is selected from the group consisiting of trifluoroacetate, chloride, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzensulfonate and p-toluenesulfonate.

73. The composition of claim 71 wherein the salt is trifluoroacetate.

74. The composition of claim 71 wherein the salt is a pharmaceutically acceptable salt.

75. The composition of claim 12 wherein the rhodamine dye having the structure of

76. The composition of claim 75 wherein the rhodamine dye is a salt.

77. The composition of claim 76 wherein the salt is selected from the group consisiting of trifluoroacetate, chloride, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzensulfonate and p-toluenesulfonate.

78. The composition of claim 76 wherein the salt is trifluoroacetate.

79. The composition of claim 76 wherein the salt is a pharmaceutically acceptable salt.

80. The composition of claim 12 wherein the rhodamine dye having the structure of

81. The composition of claim 80 wherein the rhodamine dye is a salt.

82. The composition of claim 81 wherein the salt is selected from the group consisiting of trifluoroacetate, chloride, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzensulfonate and p-toluenesulfonate.

83. The composition of claim 81 wherein the salt is trifluoroacetate.

84. The composition of claim 81 wherein the salt is a pharmaceutically acceptable salt.

85. The composition of claim 12 wherein the rhodamine dye having the structure of

86. The composition of claim 85 wherein the rhodamine dye is a salt.

87. The composition of claim 86 wherein the salt is selected from the group consisiting of trifluoroacetate, chloride, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzensulfonate and p-toluenesulfonate.

88. The composition of claim 86 wherein the salt is trifluoroacetate.

89. The composition of claim 86 wherein the salt is a pharmaceutically acceptable salt.

The composition of claim 12 wherein the rhodamine dye having the structure of

91. The composition of claim 90 wherein the rhodamine dye is a salt.

92. The composition of claim 91 wherein the salt is selected from the group consisiting of trifluoroacetate, chloride, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzensulfonate and p-toluenesulfonate.

93. The composition of claim 91 wherein the salt is trifluoroacetate.

94. The composition of claim 91 wherein the salt is a pharmaceutically acceptable salt.

95. The composition of claim 12 wherein the rhodamine dye having the structure of

96. The composition of claim 95 wherein the rhodamine dye is a salt.

97. The composition of claim 96 wherein the salt is selected from the group consisiting of trifluoroacetate, chloride, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzensulfonate and p-toluenesulfonate.

98. The composition of claim 96 wherein the salt is trifluoroacetate.

99. The composition of claim 96 wherein the salt is a pharmaceutically acceptable salt.

100. The composition of claim 12 wherein the rhodamine dye having the structure of

101. The composition of claim 100 wherein the rhodamine dye is a salt.

102. The composition of claim 101 wherein the salt is selected from the group consisiting of trifluoroacetate, chloride, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzensulfonate and p-toluenesulfonate.

103. The composition of claim 101 wherein the salt is trifluoroacetate.

104. The composition of claim 101 wherein the salt is a pharmaceutically acceptable salt.

105. The composition of claim 12 wherein the rhodamine dye having the structure of

106. The composition of claim 105 wherein the rhodamine dye is a salt.

107. The composition of claim 106 wherein the salt is selected from the group consisiting of trifluoroacetate, chloride, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzensulfonate and p-toluenesulfonate.

108. The composition of claim 106 wherein the salt is trifluoroacetate.

109. The composition of claim 106 wherein the salt is a pharmaceutically acceptable salt.

110. The composition of claim 12 wherein the rhodamine dye having the structure of

111. The composition of claim 110 wherein the rhodamine dye is a salt.

112. The composition of claim 111 wherein the salt is selected from the group consisiting of trifluoroacetate, chloride, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzensulfonate and p-toluenesulfonate.

113. The composition of claim 111 wherein the salt is trifluoroacetate.

114. The composition of claim 111 wherein the salt is a pharmaceutically acceptable salt.

115. A composition comprising a conjugation product formed from conjugating the composition of claim 1, claim 8 or claim 12 with another molecule.

116. The composition of claim 115 wherein the other molecule is a macromolecule.

117. The composition of claim 116 wherein the macromeolecule is selected from the group consisting of polymers, proteins, dextrans, celluloses, carbohydrates, lipids and nucleic acids.

118. The composition of claim 116 wherein the protein is an antibody.

119. The composition of claim 116 wherein the nucleic acid is a DNA or an RNA.